Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India
2010

Drug Resistance After Nevirapine in Pregnant Women

Sample size: 26 publication Evidence: moderate

Author Information

Author(s): Rajesh Lakshmi, Ramesh K. Hanna, Luke Elizabeth Narayanan, P.R. Swaminathan, Soumya

Primary Institution: Tuberculosis Research Centre (ICMR), Chennai, India

Hypothesis

What is the pattern and prevalence of HIV drug resistance in pregnant women exposed to single dose nevirapine?

Conclusion

A high rate of NNRTI class resistance was observed among women treated with single-dose nevirapine, despite no baseline drug resistance.

Supporting Evidence

  • No major mutations were observed in any drug class at baseline.
  • 33% of women treated with Sd-NVP developed NNRTI resistance mutations post-delivery.
  • None of the infants tested were found to be HIV-positive.

Takeaway

When pregnant women took a single dose of nevirapine to prevent passing HIV to their babies, many developed resistance to the drug afterward.

Methodology

HIV-infected, ART-naive primigravidae aged 18-25 were recruited and tested for drug resistance during pregnancy and one month after delivery.

Potential Biases

Follow-up was challenging as many women delivered in cities and returned to their native places.

Limitations

The study had a small sample size and only 20 specimens were analyzable.

Participant Demographics

HIV-infected pregnant women, ART-naive, aged 18-25, attending government antenatal clinics.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 22-44%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication